The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Intravascular hemolysis and the pathophysiology of sickle cell disease
Open accessAbstract
flow, normoxia to hypoxia, isotonic to hypertonic environment, and acidotic to alkalotic milieu.Multiple components contribute to sickle hemoglobinopathy pathophysiology, including primary components arising from HbS polymerization and secondary components that are downstream effects of the HbS polymer. Understanding how these components' complexity is compounded by genetic and environmental modulation provides insight into the well-known clinical heterogeneity of sickle cell disease (SCD).A cardinal feature of SCD pathogenesis involves inflammation, accompanied by heterocellular leukocyte-platelet-erythrocyte-endothelial adhesive events that trigger vaso-occlusive episodes, acute organ ischemia, and reperfusion injury.Twenty-five years ago, epidemiological studies identified leukocytosis, lower HbF levels, and higher total hemoglobin levels as risk factors associated with increasing incidence of acute painful episodes and acute chest syndrome (ACS) (5).The independent association of high total hemoglobin levels with more pain, ACS events, and osteonecrosis was never mechanistically explained; however, it was implied to be a result of increased blood viscosity (Table 1).Recent epidemiological studies found that lower hemoglobin levels and higher intensity of steady-state hemolytic anemia consistently associate with vasculopathic complications of disease, such as stroke, leg ulcers, PH, priapism, and renal failure.This suggests that certain subphenotypes of SCD relate more to hemolytic anemia severity rather than sickle vaso-occlusion.The reader is referred to recent reviews describing the exceptional strides made in understanding the roles of red cell rigidity (6), inflammation, and cell adhesion in sickle vaso-occlusion (7-9).Here, we review the complementary role of intravascular hemolysis and anemia.Hemolysis is a fundamental feature of sickle cell anemia that contributes to its pathophysiology and phenotypic variability.Decompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are all products of hemolysis that promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical complications of pulmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic kidney disease, and large-artery ischemic stroke.Nitric oxide (NO) is inactivated by cell-free hemoglobin in a dioxygenation reaction that also oxidizes hemoglobin to methemoglobin, a non-oxygen-binding form of hemoglobin that readily loses heme.Circulating hemoglobin and heme represent erythrocytic danger-associated molecular pattern (eDAMP) molecules, which activate the innate immune system and endothelium to an inflammatory, proadhesive state that promotes sickle vaso-occlusion and acute lung injury in murine models of sickle cell disease.Intravascular hemolysis can impair NO bioavailability and cause oxidative stress, altering redox balance and amplifying physiological processes that govern blood flow, hemostasis, inflammation, and angiogenesis.These pathological responses promote regional vasoconstriction and subsequent blood vessel remodeling.Thus, intravascular hemolysis represents an intrinsic mechanism for human vascular disease that manifests clinical complications in sickle cell disease and other chronic hereditary or acquired hemolytic anemias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“As HbF falls and fewer F-cells are protected from HbS polymer damage, the propensity for vascular occlusion and intravascular hemolysis increases with the release of heme products into the circulation that scavenge nitric oxide causing endothelial damage and vasculopathy.[57][58][59]”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Once released, IL-1β binds to IL-1 receptor (IL-1R) on leukocytes and vascular cells, promoting a cascade of downstream events that lead to activation of neutrophils and platelets and upregulation of E-selectin, P-selectin, VCAM-1, ICAM-1, and chemokines such as IL-8 in endothelial cells, all of which promote vaso-occlusion (14, 17) (Figure 1).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaso-occlusion contributes to ischemia-reperfusion injury, which, along with release of eDAMPs, promotes the progression of sterile inflammation (Figure 1d) in SCD (14, 17, 18).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies in adults with SCD lend further support to the role of hemolysis by showing a link between the hyperhemolysis phenotype of SCD and stroke risk (17).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Unequal protection by HbF across the gamut of sickle cell disease complications might be partially explained by differences in the pathophysiologic roots of these complications.57,58”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Acute painful episodes and acute chest syndrome are a result of sickle vasoocclusion; HbF has the most noticeable beneficial effect on these subphenotypes.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Priapism, nephropathy, and sickle vasculopathy are associated with hemolysis.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival in Patients with Primary Pulmonary Hypertension
D’Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. Μ., Kernis, J. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-5-343 · Cited by 3,488
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 1×
“Mortality Increases risk (19, 39, 42, 47, 49, 64, 188) Protective (189) Protective (190)”
Self-citationCerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
Rother, R. P., Bell, L. B., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,565
Self-citationPain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Self-citationPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationCell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., et al. (2002) · Nature Medicine · doi:10.1038/nm799 · Cited by 1,097
Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876
Self-citationCastro, O. L., Brambilla, D. J., Thorington, B. D., Reindorf, C. A., Scott, R., GILLETTE, P. N., Vera, J., & Levy, P. S. (1994) · Blood · doi:10.1182/blood.v84.2.643.643 · Cited by 805
Research works printed but not linked: 1
- 10.1038/nm1202-799 · DOI · Paper page
Cited by
Sorted by citations
Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Self-citationPathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
Self-citationA Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
Vichinsky, E. P., Hoppe, C. C., Ataga, K. I., Ware, R. E., Nduba, V., El-Beshlawy, A. M., Hassab, H. M. A., Achebe, M. M., Alkindi, S. S. A., Brown, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903212 · Cited by 634
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H. T. T., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 586
Arginase: A Multifaceted Enzyme Important in Health and Disease
Caldwell, R. W., Rodriguez, P. C., Toque, H. A., Narayanan, S. P., & Caldwell, R. B. (2018) · Physiological Reviews · doi:10.1152/physrev.00037.2016 · Cited by 495
Squeezing for Life – Properties of Red Blood Cell Deformability
Huisjes, R., Bogdanova, A. Y., van Solinge, W. W., Schiffelers, R. M., Kaestner, L., & van Wijk, R. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00656 · Cited by 331
Pro-inflammatory Actions of Heme and Other Hemoglobin-Derived DAMPs
Bozza, M. T., & Jeney, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01323 · Cited by 213
The Red Blood Cell—Inflammation Vicious Circle in Sickle Cell Disease
Nader, É., Romana, M., & Connes, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00454 · Cited by 207
Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles
Merle, N. S., Grünenwald, A., Rajaratnam, H., Gnemmi, V., Frimat, M., Figueres, L., Knockaert, S., Bouzekri, S., Charue, D., Noé, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96910 · Cited by 194
Non-enzymatic hydrogen sulfide production from cysteine in blood is catalyzed by iron and vitamin B6
Yang, J., Minkler, P. E., Grove, D., Wang, R., Willard, B. B., Dweik, R. A., & Hine, C. (2019) · Communications Biology · doi:10.1038/s42003-019-0431-5 · Cited by 186
Therapeutic strategies for sickle cell disease: towards a multi-agent approach
Telen, M. J., Malik, P., & Vercellotti, G. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0003-2 · Cited by 188
Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics
Vallelian, F., Buehler, P. W., & Schaer, D. J. (2022) · Blood · doi:10.1182/blood.2022015596 · Cited by 173
Understanding Sickle cell disease: Causes, symptoms, and treatment options
Elendu, C., Amaechi, D. C., Alakwe-Ojimba, C. E., Elendu, T. C., Elendu, R. C., Ayabazu, C. P., Aina, T. O., Aborisade, O., & Adenikinju, J. S. (2023) · Medicine · doi:10.1097/md.0000000000035237 · Cited by 189
Wei, Z., Wang, L., Tang, C., Chen, S., Wang, Z., Wang, Y., Bao, J., Xie, Y., Zhao, W., Su, B., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202002234 · Cited by 161
Red blood cell dysfunction: a new player in cardiovascular disease
Pernow, J., Mahdi, A., Yang, J., & Zhou, Z. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz156 · Cited by 163
The Dual Role of Myeloperoxidase in Immune Response
Arnhold, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218057 · Cited by 172
cGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development
Friebe, A., Sandner, P., & Schmidtko, A. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01779-z · Cited by 139
Fetal hemoglobin in sickle cell anemia
Steinberg, M. H. (2020) · Blood · doi:10.1182/blood.2020007645 · Cited by 136
Self-citationDisorders of erythrocyte hydration
Gallagher, P. G. (2017) · Blood · doi:10.1182/blood-2017-04-590810 · Cited by 144
Nanoparticle Properties Modulate Their Attachment and Effect on Carrier Red Blood Cells
Pan, D. C., Myerson, J. W., Brenner, J. S., Patel, P., Anselmo, A. C., Mitragotri, S., & Muzykantov, V. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-19897-8 · Cited by 123
The Worst Things in Life are Free: The Role of Free Heme in Sickle Cell Disease
Gbotosho, O. T., Kapetanaki, M. G., & Kato, G. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.561917 · Cited by 118
Self-citationOxidants and Antioxidants in the Redox Biochemistry of Human Red Blood Cells
Möller, M. N., Orrico, F., Villar, S. F., López, A. C., Silva, N., Donzé, M., Thomson, L., & Denicola, A. (2022) · ACS Omega · doi:10.1021/acsomega.2c06768 · Cited by 123
Sickle Cell Disease: Role of Oxidative Stress and Antioxidant Therapy
Vona, R., Sposi, N. M., Mattia, L., Gambardella, L., Straface, E., & Pietraforte, D. (2021) · Antioxidants · doi:10.3390/antiox10020296 · Cited by 122
Howard, J., Ataga, K. I., Brown, R. C., Achebe, M., Nduba, V., El-Beshlawy, A. M., Hassab, H. M. A., Agodoa, I., Tonda, M. E., Gray, S., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00059-4 · Cited by 107
Synthetic oligosaccharides can replace animal-sourced low–molecular weight heparins
Xu, Y., Chandarajoti, K., Zhang, X., Pagadala, V., Dou, W., Hoppensteadt, D., Sparkenbaugh, E., Cooley, B. C., Daily, S., Key, N. S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5954 · Cited by 106
Sickle cell disease: Clinical presentation and management of a global health challenge
Houwing, M. E., de Pagter, P. J., van Beers, E. J., Biemond, B. J., Rettenbacher, E., Rijneveld, A. W., Schols, E. M., Philipsen, J. N. J., Tamminga, R. Y. J., van Draat, K. F., et al. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.05.004 · Cited by 106
Page, G. P., Kanias, T., Guo, Y., Lanteri, M. C., Zhang, X., Mast, A. E., Cable, R. G., Spencer, B. R., Kiss, J. E., Fang, F., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146077 · Cited by 103
Self-citationTargeting novel mechanisms of pain in sickle cell disease
Tran, H., Gupta, M., & Gupta, K. (2017) · Blood · doi:10.1182/blood-2017-05-782003 · Cited by 96
Vats, R., Brzóska, T., Bennewitz, M. F., Jimenez, M. A., Pradhan‐Sundd, T., Tütüncüoğlu, E., Jonassaint, J., Gutierrez, E., Watkins, S. C., Shiva, S., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1370oc · Cited by 99
Self-citationThromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance
Conran, N., & Paula, E. V. D. (2020) · Haematologica · doi:10.3324/haematol.2019.239343 · Cited by 101
Physical Properties of Blood and their Relationship to Clinical Conditions
Alexy, T., Detterich, J. A., Connes, P., Tóth, K., Nader, É., Kenyeres, P., Arriola‐Montenegro, J., Ülker, P., & Simmonds, M. J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.906768 · Cited by 94
Emerging disease-modifying therapies for sickle cell disease
Carden, M. A., & Little, J. A. (2019) · Haematologica · doi:10.3324/haematol.2018.207357 · Cited by 100
Haptoglobin Therapeutics and Compartmentalization of Cell-Free Hemoglobin Toxicity
Buehler, P. W., Humar, R., & Schaer, D. J. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.02.004 · Cited by 90
Tebbi, C. K. (2022) · Hemato · doi:10.3390/hemato3020024 · Cited by 110
Redox signaling in the pancreas in health and disease
Sastre, J., Pérez, S., Sabater-Orti, L., & Rius‐Pérez, S. (2024) · Physiological Reviews · doi:10.1152/physrev.00044.2023 · Cited by 101
The multifaceted role of ischemia/reperfusion in sickle cell anemia
Hebbel, R. P., Belcher, J. D., & Vercellotti, G. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133639 · Cited by 85
Determinants of severity in sickle cell disease
Rees, D. C., Brousse, V. A. M., & Brewin, J. N. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100983 · Cited by 93
Hopp, M.-T., Schmalohr, B. F., Kühl, T., Detzel, M. S., Wißbrock, A., & Imhof, D. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c00415 · Cited by 84
Erythrocytes as a preferential target of oxidative stress in blood
Fujii, J., Homma, T., Kobayashi, S., Warang, P. P., Madkaikar, M. R., & Mukherjee, M. B. (2021) · Free Radical Research · doi:10.1080/10715762.2021.1873318 · Cited by 85
Xu, J. Z., Conrey, A. K., Frey, I., Gwaabe, E., Menapace, L. A., Tumburu, L., Lundt, M., Lequang, T., Li, Q., Glass, K. E., et al. (2022) · Blood · doi:10.1182/blood.2022015403 · Cited by 76
Park, S., Mattè, A., Jung, Y., Ryu, J., Anand, W., Han, E.-Y., Liu, M., Carbone, C., Melisi, D., Nagasawa, T., et al. (2020) · Blood · doi:10.1182/blood.2019002227 · Cited by 69
Stefanova, D., Raychev, A., Deville, J., Humphries, R., Campeau, S., Ruchala, P., Nemeth, E., Ganz, T., & Bulut, Y. (2018) · Infection and Immunity · doi:10.1128/iai.00253-18 · Cited by 68
Ascorbic acid attenuates endothelial permeability triggered by cell-free hemoglobin
Kuck, J. L., Bastarache, J. A., Shaver, C. M., Fessel, J. P., Dikalov, S., May, J. M., & Ware, L. B. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.058 · Cited by 68
Clinical and genetic ancestry profile of a large multi‐centre sickle cell disease cohort in Brazil
Carneiro-Proietti, A. B. F., Kelly, S., Teixeira, C. M., Sabino, É. C., Alencar, C. S., Capuani, L., Salomon, T., Araújo, A. D. S., Loureiro, P. R. A. D. C., Máximo, C., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15462 · Cited by 65
Vats, R., Kaminski, T. W., Brzóska, T., Leech, J. A., Tütüncüoğlu, E., Katoch, O., Jonassaint, J., Tejero, J., Novelli, E. M., Pradhan‐Sundd, T., et al. (2022) · Blood · doi:10.1182/blood.2021014552 · Cited by 65
Self-citationFocus on Early Events: Pathogenesis of Pulmonary Arterial Hypertension Development
Rafikova, O., Ghouleh, I. A., & Rafikov, R. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7673 · Cited by 66
Oxidative pathways in the sickle cell and beyond
Alayash, A. I. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.05.009 · Cited by 63
Nader, É., Romana, M., Guillot, N., Fort, R., Stauffer, É., Lemonne, N., Garnier, Y., Skinner, S. C., Etienne‐Julan, M., Robert, M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.551441 · Cited by 69
Prothrombotic aspects of sickle cell disease
Sparkenbaugh, E., & Pawliński, R. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13717 · Cited by 62
Meegan, J. E., Shaver, C. M., Putz, N. D., Jesse, J. J., Landstreet, S. R., Lee, H. N. R., Sidorova, T. N., McNeil, J. B., Wynn, J. L., Cheung‐Flynn, J., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228727 · Cited by 62
The Multiple Facets of Iron Recycling
Slusarczyk, P., & Mleczko‐Sanecka, K. (2021) · Genes · doi:10.3390/genes12091364 · Cited by 64
Li, W., Guo, R., Song, Y., & Jiang, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.613885 · Cited by 62
Allali, S., Rignault‐Bricard, R., de Montalembert, M., Taylor, M., Bouceba, T., Hermine, O., & Maciel, T. T. (2022) · Blood · doi:10.1182/blood.2021014894 · Cited by 64
Vinchi, F., Sparla, R., Passos, S., Sharma, R., Vance, S. Z., Zreid, H., Juaidi, H., Manwani, D. G., Yazdanbakhsh, K., Nandi, V., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17361 · Cited by 57
Hemolysis and immune regulation
Zhong, H., & Yazdanbakhsh, K. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000423 · Cited by 59
Heme scavenging reduces pulmonary endoplasmic reticulum stress, fibrosis, and emphysema
Aggarwal, S., Ahmad, I., Lam, A., Carlisle, M. A., Li, C., Wells, J. M., Raju, S. V., Athar, M., Rowe, S. M., Dransfield, M. T., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120694 · Cited by 54
Ferroptosis regulates hemolysis in stored murine and human red blood cells
D’Alessandro, A., Keele, G. R., Hay, A. M., Nemkov, T. G., Earley, E. J., Stephenson, D., Vincent, M. J., Deng, X., Stone, M., Dzieciątkowska, M., et al. (2024) · Blood · doi:10.1182/blood.2024026109 · Cited by 57
Cardiovascular complications in patients with sickle cell disease
Gladwin, M. T. (2017) · Hematology · doi:10.1182/asheducation-2017.1.423 · Cited by 56
Self-citationYalamanoglu, A., Deuel, J., Hunt, R., Baek, J. H., Hassell, K. L., Redinius, K., Irwin, D. C., Schaer, D. J., & Buehler, P. W. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00269.2018 · Cited by 53
Liu, Y., Pal, M., Bao, W., Shi, P. A., Lobo, C. A., An, X., Manwani, D. G., Zhong, H., & Yazdanbakhsh, K. (2021) · Blood · doi:10.1182/blood.2021011629 · Cited by 52
Kucukal, E., Ilich, A., Key, N. S., Little, J. A., & Gurkan, U. A. (2018) · American Journal of Hematology · doi:10.1002/ajh.25159 · Cited by 54
Václavů, L., Meynart, B. N., Mutsaerts, H. J. M. M., Petersen, E. T., Majoie, C. B. L. M., VanBavel, E., Wood, J. C., Nederveen, A. J., & Biemond, B. J. (2018) · Haematologica · doi:10.3324/haematol.2018.206094 · Cited by 53
Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease
Osunkwo, I., Manwani, D. G., & Kanter, J. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620720955000 · Cited by 57
HO-1hi patrolling monocytes protect against vaso-occlusion in sickle cell disease
Liu, Y., Jing, F., Yi, W., Mendelson, A., Shi, P., Walsh, R., Friedman, D. F., Minniti, C., Manwani, D., Chou, S. T., et al. (2018) · Blood · doi:10.1182/blood-2017-12-819870 · Cited by 51
Fetal hemoglobin in sickle cell anemia: The Arab‐Indian haplotype and new therapeutic agents
Habara, A. H., Mohammed, E. S. E., & Steinberg, M. H. (2017) · American Journal of Hematology · doi:10.1002/ajh.24872 · Cited by 51
Self-citationCardiovascular manifestations of sickle cell disease
Hammoudi, N., Lionnet, F., Redheuil, A. B., & Montalescot, G. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz217 · Cited by 54
Erythrocytes: Central Actors in Multiple Scenes of Atherosclerosis
Turpin, C., Catan, A., Meilhac, O., Bourdon, E., Canonne‐Hergaux, F., & Rondeau, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115843 · Cited by 53
Liu, Y., Zhong, H., Bao, W., Mendelson, A., An, X., Shi, P. A., Chou, S. T., Manwani, D. G., & Yazdanbakhsh, K. (2019) · Blood · doi:10.1182/blood.2019000172 · Cited by 51
Alimohamadi, H., Smith, A. S., Nowak, R. B., Fowler, V. M., & Rangamani, P. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007890 · Cited by 48
Wonkam, A., Mnika, K., Bitoungui, V. J. N., Chemegni, B. C., Chimusa, E. R., Dandara, C., & Kengne, A. P. (2017) · British Journal of Haematology · doi:10.1111/bjh.15011 · Cited by 47
Merle, N. S., Boudhabhay, I., Léon, J., Frémeaux‐Bacchi, V., & Roumenina, L. T. (2019) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2019.02.008 · Cited by 49
Yalçınkaya, A. S., Ünal, S., & Öztaş, Y. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1174-5 · Cited by 47
Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives
de Azevedo, J. T. C., & Malmegrim, K. C. R. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.04.012 · Cited by 46
Hazzazi, A., Ageeli, M. H., Alfaqih, A. M., Jaafari, A., Malhan, H. M., & Bakkar, M. (2020) · Journal of Applied Hematology · doi:10.4103/joah.joah_67_19 · Cited by 45
Hypercoagulable state in sickle cell disease
Faës, C., Sparkenbaugh, E., & Pawliński, R. (2018) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-189013 · Cited by 45
How I diagnose and treat venous thromboembolism in sickle cell disease
Shet, A. S., & Wun, T. (2018) · Blood · doi:10.1182/blood-2018-03-822593 · Cited by 46
Olatunya, O. S., Lanaro, C., Longhini, A. L. F., Franco‐Penteado, C. F., Fertrin, K. Y., Adekile, A. D., Saad, S. T. O., & Costa, F. F. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03792-x · Cited by 43
Drug Therapies for the Management of Sickle Cell Disease
Rai, P., & Ataga, K. I. (2020) · F1000Research · doi:10.12688/f1000research.22433.1 · Cited by 43
Onalo, R., Cooper, P., Cilliers, A. M., Vorster, B. C., Nnebe‐Agumadu, U., Oluseyi, O. O., Onalo, V. D., Zubairu, Y., Ayodele‐Kehinde, A. U., Damilare, O. M., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.26028 · Cited by 43
Vinchi, F. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8167 · Cited by 45
Veluswamy, S., Shah, P., Denton, C. C., Chalacheva, P., Khoo, M. C. K., & Coates, T. D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101690 · Cited by 41
Gentinetta, T., Belcher, J. D., Brügger‐Verdon, V., Adam, J., Ruthsatz, T., Bain, J., Schu, D. J., Ventrici, L., Edler, M., Lioe, H., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030630 · Cited by 41
Self-citationRevisiting anemia in sickle cell disease and finding the balance with therapeutic approaches
Xu, J. Z., & Thein, S. L. (2022) · Blood · doi:10.1182/blood.2021013873 · Cited by 39
Sil, R., & Chakraborti, A. S. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1543455 · Cited by 42
Hare, G. M. T., Han, K., Leshchyshyn, Y., Mistry, N., Kei, T., Dai, S. Y., Tsui, A. K. Y., Pirani, R. A., Honavar, J., Patel, R. P., et al. (2018) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-018-1140-0 · Cited by 39
Li, Y., Han, M., Wang, Y., Liu, Q., Zhao, W., Su, B., & Zhao, C. (2018) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2018.08.118 · Cited by 39
Redinus, K., Baek, J. H., Yalamanoglu, A., Shin, H. K., Moldova, R., Harral, J. W., Swindle, D. C., Pak, D. I., Ferguson, S. K., Nuss, R., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127860 · Cited by 39
Farrell, A. T., Panepinto, J. A., Desai, A. A., Kassim, A. A., Lebensburger, J. D., Walters, M. C., Bauer, D. E., Blaylark, R. M., DiMichele, D., Gladwin, M. T., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000883 · Cited by 41
Self-citationDeficient mitophagy pathways in sickle cell disease
Martino, S., Arlet, J., Odièvre, M., Jullien, V., Moras, M., Hattab, C., Lefèbvre, T., Gouya, L., Ostuni, M. A., Lefevre, S. D., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17416 · Cited by 43
Hsp90 in Human Diseases: Molecular Mechanisms to Therapeutic Approaches
Sumi, M. P., & Ghosh, A. (2022) · Cells · doi:10.3390/cells11060976 · Cited by 42
Measuring Intracellular Viscosity in Conditions of Hypergravity
Woodcock, E. M., Girvan, P., Eckert, J., López‐Duarte, I., Kubánková, M., van Loon, J. J. W. A., Brooks, N. J., & Kuimova, M. K. (2019) · Biophysical Journal · doi:10.1016/j.bpj.2019.03.038 · Cited by 38
Bories, G. F. P., Yeudall, S., Serbulea, V., Fox, T. E., Isakson, B. E., & Leitinger, N. (2020) · Blood · doi:10.1182/blood.2020004964 · Cited by 38
Glaros, A. K., Razvi, R., Shah, N., & Zaidi, A. U. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211001136 · Cited by 40
Sickle cell disease as an accelerated aging syndrome
Idris, I. M., Botchwey, E. A., & Hyacinth, H. I. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702211068522 · Cited by 37
Yan, J., Wang, Y., Song, X., Yan, X., Zhao, Y., Yu, L., & He, Z. (2022) · Small Methods · doi:10.1002/smtd.202200139 · Cited by 37
Lee, M. T., Kattan, M., Fennoy, I., Arpadi, S. M., Miller, R. L., Cremers, S., McMahon, D. J., Nieves, J. W., & Brittenham, G. M. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017013979 · Cited by 36
Sickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study
Clift, A. K., Saatci, D., Coupland, C. A. C., Dambha‐Miller, H., & Hippisley‐Cox, J. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1375 · Cited by 36
Vallelian, F., Buzzi, R. M., Pfefferlé, M., Yalamanoglu, A., Dubach, I. L., Wassmer, A., Gentinetta, T., Hansen, K., Humar, R., Schulthess, N., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00932-1 · Cited by 33
The clinical relevance of heme detoxification by the macrophage heme oxygenase system
Yeudall, S., Upchurch, C. M., & Leitinger, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1379967 · Cited by 36
New insights into the pathophysiology and development of novel therapies for sickle cell disease
Moerdler, S., & Manwani, D. G. (2018) · Hematology · doi:10.1182/asheducation-2018.1.493 · Cited by 35
Metadata
- Authors
- Kato, G. J., Steinberg, M. H., & Gladwin, M. T.
- Affiliations
- University of Pittsburgh (US)
- Boston University (US)
- Corresponding author
- Gladwin, Mark T.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-03-01
- Volume
- 127
- Issue
- 3
- Pages
- 750-760
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5330745
- OpenAlex
- W2592339311
- Semantic Scholar
- 0c9beb4e3a557982862ac3ec381a89baab12ceae
- Cited by
- 748
- References
- 193
- Citations by year
- 2026: 90 · 2025: 81 · 2024: 76 · 2023: 65 · 2022: 116 · 2021: 81 · 2020: 87 · 2019: 76 · 2018: 53 · 2017: 21
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Patient-Centered Outcomes Research Institute
- University of Pittsburgh
- Hemophilia Center of Western Pennsylvania
- National Institutes of Health (HL098032)
- National Heart, Lung, and Blood Institute (R01HL087681, R01HL068970, P01HL103455, RC2HL101212, R01HL121386, U01HL107443, T32HL007501, R01HL125886, R01HL098032, T32HL110849)
- National Institute on Minority Health and Health Disparities (R01MD009162)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Hematology › Blood properties and coagulation
- Keywords
- intravascular hemolysis, sickle cell disease, free hemoglobin, nitric oxide, methemoglobin, heme, arginase-1, asymmetric dimethylarginine, adenine nucleotides, pulmonary hypertension, inflammation
- MeSH terms
- Anemia, Sickle Cell, Hemolysis, Humans, Methemoglobin, Nitric Oxide, Vascular Diseases, Vasomotor System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
